Improving how patients engage in genomic testing for rare cancers
Engagement Optimization Unit
['FUNDING_OTHER'] · WASHINGTON UNIVERSITY · NIH-10924012
This study is all about finding better ways to connect with patients who have rare cancers, like cholangiocarcinoma, multiple myeloma, and early onset colorectal cancer, especially those from underserved communities, so they can better understand and feel comfortable with genomic testing and results.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | WASHINGTON UNIVERSITY (nih funded) |
| Locations | 1 site (SAINT LOUIS, UNITED STATES) |
| Trial ID | NIH-10924012 on ClinicalTrials.gov |
What this research studies
The Engagement Optimization Unit at Washington University focuses on enhancing the ways patients are recruited, consented, and communicated with regarding genomic testing for rare cancers. This research aims to develop better methods for engaging patients, particularly those from underserved populations, in the genomic characterization process. By conducting evaluations and randomized trials, the project seeks to improve the overall experience and understanding of genomic results for patients diagnosed with cholangiocarcinoma, multiple myeloma, and early onset colorectal cancer. The research will also address ethical concerns related to genomic testing and ensure that patient feedback is integrated into the engagement process.
Who could benefit from this research
Good fit: Ideal candidates include patients diagnosed with cholangiocarcinoma, multiple myeloma, or early onset colorectal cancer, especially those from minority or rural backgrounds.
Not a fit: Patients with common cancers or those not interested in genomic testing may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved patient experiences and outcomes in genomic testing for rare cancers.
How similar studies have performed: Similar research has shown promise in optimizing patient engagement in genomic studies, indicating that this approach could be effective.
Where this research is happening
SAINT LOUIS, UNITED STATES
- WASHINGTON UNIVERSITY — SAINT LOUIS, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: DRAKE, BETTINA F. — WASHINGTON UNIVERSITY
- Study coordinator: DRAKE, BETTINA F.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancer Center, Cancer Patient, Cancers